Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas

NCT02158975 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, T-Cell

Interventions

DRUG: MLN9708

Sponsor

University of Michigan Rogel Cancer Center